Matinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) is scheduled to be announcing its earnings results on Wednesday, March 13th.
Matinas BioPharma Price Performance
Shares of NYSEAMERICAN:MTNB opened at $0.27 on Tuesday. The company has a market capitalization of $58.66 million, a price-to-earnings ratio of -2.45 and a beta of 1.52. Matinas BioPharma has a 12-month low of $0.11 and a 12-month high of $0.89.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in MTNB. BlackRock Inc. raised its stake in Matinas BioPharma by 0.7% in the 1st quarter. BlackRock Inc. now owns 4,325,053 shares of the company's stock valued at $3,479,000 after purchasing an additional 29,643 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new stake in Matinas BioPharma in the 1st quarter valued at $32,000. HRT Financial LP grew its holdings in Matinas BioPharma by 320.5% in the 4th quarter. HRT Financial LP now owns 54,567 shares of the company's stock valued at $27,000 after buying an additional 41,590 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Matinas BioPharma by 42.0% in the 1st quarter. Renaissance Technologies LLC now owns 171,929 shares of the company's stock valued at $81,000 after buying an additional 50,833 shares in the last quarter. Finally, State Street Corp grew its holdings in Matinas BioPharma by 8.0% in the 1st quarter. State Street Corp now owns 712,471 shares of the company's stock valued at $573,000 after buying an additional 52,897 shares in the last quarter. 11.90% of the stock is owned by institutional investors and hedge funds.
Matinas BioPharma Company Profile
(
Get Free Report)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Matinas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Matinas BioPharma wasn't on the list.
While Matinas BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
